Orelabrutinib

Orelabrutinib
Clinical data
Trade names	宜诺凯
Other names	ICP-022; ICP022
ATC code	L01EL04 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name 2-(4-Phenoxyphenyl)-6-(1-prop-2-enoylpiperidin-4-yl)pyridine-3-carboxamide;
CAS Number	1655504-04-3;
PubChem CID	91667513;
IUPHAR/BPS	10629;
DrugBank	DB16272;
ChemSpider	82956396;
UNII	WJA5UO9E10;
ChEMBL	ChEMBL4650321;
Chemical and physical data
Formula	C26H25N3O3
Molar mass	427.504 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C=CC(=O)N1CCC(CC1)C2=NC(=C(C=C2)C(=O)N)C3=CC=C(C=C3)OC4=CC=CC=C4;
	InChI InChI=1S/C26H25N3O3/c1-2-24(30)29-16-14-18(15-17-29)23-13-12-22(26(27)31)25(28-23)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-13,18H,1,14-17H2,(H2,27,31); Key:MZPVEMOYADUARK-UHFFFAOYSA-N;

Orelabrutinib is a drug for the treatment of cancer.

In China, it is approved for patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), who have received at least one treatment in the past.^[1]

References